3D MR Versus 3D CT for Glenohumeral Arthritis
This study aims to assess the efficacy of three-dimensional magnetic resonance (MR) compared to three-dimensional computed tomography (CT) imaging. This proposed study is a prospective, unrandomized, single-blinded, self-controlled, and single-armed diagnostic radiological evaluation study.
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||18 Years and Over|
- - Patients suffering from glenohumeral OA; - Radiographic evidence of severe glenoid erosion; - Indication for TSA based on clinical exam; - Patient is willing to participate by complying with pre-operative visit requirements; - Patient is willing and able to review and sign a study informed consent form.
- - Prior arthroplasty at the affected shoulder; - Patients with inflammatory arthritis; - Patients with post-capsulorrhaphy arthritis; - Patients with post-traumatic arthritis; - Patients with rotator cuff tear arthropathy; - Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedures; - Patients who are pregnant; - Patients with implanted medical devices that are contraindicated to exposure up to a 3.0-tesla magnetic field.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|NYU Langone Health|
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Joseph D Zuckerman, MD|
|Principal Investigator Affiliation||NYU Langone Health|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
|Arthritis, Glenohumeral Osteoarthritis|
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.